From Seed to Unicorn: Enveda’s Journey to Building a Next-Gen Pharma Company

Session details:

In less than five years, Enveda has grown from a seed-stage startup into a unicorn, advancing its first of many candidates into the clinic while building one of the most ambitious AI platforms and portfolios in biotech.

In this fireside chat, Viswa Colluru, Ph.D., CEO & Founder of Enveda, joins Angelika Fretzen, Ph.D., COO of the Wyss Institute, to share Enveda’s journey, from the power of a compelling investor pitch and storytelling, to building the right team and company foundation, to translating a bold scientific vision into a clinical-stage pipeline. The discussion will highlight lessons learned in scaling at the intersection of nature and AI, and what’s next for Enveda as it redefines the future of the industry.